In a subset analysis of endocrine treatment, high tumor stromal VEGF-A was found to be a strong predictor of poor BCSS in patients receiving tamoxifen (Figure 4A; P = 0.02) but not in patients receiving aromatase inhibitors (see Additional file 4: Figure S3A: Kaplan-Meier survival estimates of BCSS and DFS in IBC patients treated with aromatase inhibitors with low and high stromal VEGF-A expression levels; P = 0.07) and patients who did not undergo endocrine therapy because of negative hormone receptor status (Figure 4C; P = 0.07). The gene discussed is VEGFA; the disease is inflammatory breast carcinoma.